ALXN News and Press, Alexion Pharmaceuticals Inc. From 03/26/19

(Rendition of Brain Neurons, Source: NIH) The biotech sector has continued to participate in the market rally. One of the reasons is the strength in biopharma M&A activity, which provides unique support for valuations and particularly assists the small-and-midcap biotech companies. We ...

Introduction - time for a deeper dive Last month, I wrote Alexion's Complementary Growth Strategy . The title is a pun on its focus on a component of the immune system - "complement" - which comprises proteins that assist in immune functions - and Alexion's ( ALXN ) growth strategy, which b...

Thinking about pipelines One of the ongoing lessons I take from observing the business world is the importance of a company taking prudent risks. Another observation as an investor is the value of companies that under-promise and over-deliver. The Biogen ( BIIB ) stock crash Thursday on t...

I’ve been following Achillion Pharmaceuticals ( ACHN ) for quite some time, but became more interested after the company reported positive results of its factor D inhibitor ACH-4471 in two rare diseases – PNH and C3G. The problem with PNH is that the results aren’t goo...

Alexion Pharmaceuticals (NASDAQ: ALXN ) will collaborate with Swedish biotech Affibody AB to develop candidate ABY-039 for rare immunoglobulin G (IgG)-mediated autoimmune disorders. More news on: Alexion Pharmaceuticals, Inc., Healthcare stocks news, Read more ...

Alexion Pharmaceuticals (NASDAQ: ALXN ) will collaborate with Zealand Pharma A/S (NASDAQ: ZEAL ) to discover and develop novel subcutaneously administered peptide therapies for complement-mediated disorders. More news on: Alexion Pharmaceuticals, Inc., Zealand Pharma A/S, Healthcare stocks...

- Collaboration furthers Alexion’s complement leadership with expansion into peptide therapies - - Agreement provides Alexion with exclusive worldwide licenses for one preclinical target, with option for up to three additional targets, in the complement pathway - - Zealand ...

- Agreement provides opportunity to expand Alexion’s clinical-stage anti-FcRn portfolio with ABY-039 - - Affibody to receive $25 million upfront payment with potential for additional milestone-dependent and royalty payments, and option for U.S. co-promote - - Affibodyȁ...

Fortress Biotech ( FBIO ) continues to make strides since bottoming out in December. Up a hefty 134% since my last coverage on December 19, plenty of upside remains for the stock. This is because Fortress’s strong jump at the end of January had nothing at all to do with my thesis for ...

Sell-Off in Biotech-Land Last week, biotechs were blindsided Tuesday when it was announced that FDA Commissioner Scott Gottlieb will be resigning imminently. A broad index of biotech stocks ((BTK)) - not an ETF (which is managed) - dropped from an intra-day high of 5,123 to close the week ne...